Biotech firm gains further cash injection to develop diarrhoea vaccines  

ACE Biosciences gets EUR 11.9 m in funding to continue development of the first commercial vaccine for traveller's diarrhoea caused by Campylobacter
Danish biotech firm ACE BioSciences, which is working on the development of the first commercial vaccine for traveller's diarrhoea caused by Campylobacter, has announced that it has raised EUR 11.9 m in funding from Sunstone Life Science Venture Fond, together with Bankinvest and Dansk Innovationsinvestering. The money will fund the company's activities up to the end of 2009.
ACE BioSciences is planning to commence Phase IIb trials of the vaccine early next year, following successful completion of initial studies in animals and humans. Campylobacter causes the more serious kind of traveller's diarrhoea, which accounts for 25% of cases worldwide. The commonest form, responsible for 50% of cases, is caused by E coli strain ETEC. ACE BioSciences is also developing a vaccine for this form, which is currently at the Phase I clinical trial stage.
It is estimated that by 2020 the number of travellers worldwide entering traveller’s diarrhoea risk regions annually may reach 190 million, of whom approximately half would be expected to develop traveller's diarrhoea. ACE BioSciences and its investors expect the annual global market for the Campylobacter vaccine to be worth EUR 350 m, and EUR 550 m for the ETEC vaccine.

ACE Biosciences' long-term plan is to develop a combined oral vaccine for both Campylobacter and ETEC, offering travellers protection from 75% of the most common causes of traveller's diarrhoea.
Link > ACE Biosciences  

Next step

Explore business cases

Please contact me

How can we help you?

We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×